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Abstract
Background
Pulmonary metastases are common in patients with primary colorectal cancer (CRC). Heat-
shock protein 27 (Hsp27) is upregulated in activated fibroblasts during wound healing and
systemically elevated in various diseases. Cancer-associated fibroblasts (CAFs) are also
thought to play a role as prognostic and predictive markers in various malignancies includ-
ing CRC. Surprisingly, the expression of Hsp27 has never been assessed in CAFs. There-
fore we aimed to investigate the expression level of Hsp27 in CAFs and its clinical
implications in patients with CRC lung metastases.
Methods
FFPE tissue samples from 51 pulmonary metastases (PMs) and 33 paired primary tumors
were evaluated for alpha-SMA, CD31, Hsp27 and vimentin expression by immunohis-
tochemistry and correlated with clinicopathological variables. 25 liver metastases served as
control group. Moreover, serum samples (n=10) before and after pulmonary metastasect-
omy were assessed for circulating phospho-Hsp27 and total Hsp27 by ELISA.
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Results
Stromal expression of Hsp27 was observed in all PM and showed strong correlation with
alpha-SMA (P<0.001) and vimentin (P<0.001). Strong stromal Hsp27 was associated with
higher microvessel density in primary CRC and PM. Moreover, high stromal Hsp27 and
αSMA expression were associated with decreased recurrence-free survival after pulmonary
metastasectomy (P=0.018 and P=0.008, respectively) and overall survival (P=0.031 and
P=0.017, respectively). Serum levels of phospho- and total Hsp27 dropped after metasta-
sectomy to levels comparable to healthy controls.
Conclusions
Herein we describe for the first time that Hsp27 is highly expressed in tumor stroma of CRC.
Stromal α-SMA and Hsp27 expressions correlate with the clinical outcome after pulmonary
metastasectomy. Moreover, serum Hsp27 might pose a future marker for metastatic dis-
ease in CRC.
Introduction
Colorectal cancer (CRC) is, after lung cancer, the second most common cause of cancer-related
death in Europe [1]. More than one fifth of the patients with CRC present with metastases al-
ready at time of diagnosis of the primary cancer and the same proportion will develop metasta-
ses during the course of disease [1, 2]. The lungs are the second most common site of distant
metastasis, making pulmonary metastases (PM) an essential contributor to the high mortality
of CRC.
Besides cancer cells themselves, a tumor comprises stromal cells. The interactions of stromal
and cancer cells is thought to be a major determinant of the tumor behavior and response to
therapy [3, 4]. Cellular components of the stroma are fibroblasts, endothelial cells, immune
cells and pericytes [5]. Cancer-associated fibroblasts (CAF), and especially activated fibroblasts,
play a major role in the tumor-stroma network, similar to dermal fibroblasts in wound healing.
This contributed to the description of tumors as “wounds that do not heal” by Dvorak et al. in
the late 80’s [6]. CAF contribute to various tumor-promoting characteristics like extra-cellular
matrix turnover, tumor growth, angiogenesis and metastasis [7, 8]. Due to the expression of α-
smooth muscle actin (α-SMA), activated CAF are often described as myofibroblasts. They have
also been shown to be positive for fibroblast-activation protein-α/seprase, palladin and vimen-
tin [9–12]. Recently, efforts have been made to characterize the “signature” of these fibroblasts
by proteome and gene expression profiling [13, 14].
In the context of benign diseases, wound healing and keloid formation it is well known that
activated fibroblasts express high levels of heat-shock protein 27 (Hsp27), which is crucial for
fibroblast adhesion, contractility and motility [15–17]. The TGF-beta induced p38-MAPK
pathway is the key regulator in the induction of Hsp27 in smooth muscle cells and myofibro-
blasts [18, 19]. Once synthesized, two main functions of Hsp27 are critical in wound healing
process: promoting myofibroblast motility and angiogenesis. Hsp27 is involved in the stabiliza-
tion of actin filaments and of SNAIL, an inducer of epithelial-mesenchymal transition. Both
mechanisms contribute to the induction of the myofibroblastic phenotype [20, 21]. Another
function of Hsp27 executed in a paracrine manner is enhancing angiogenesis. It was demon-
strated that extracellular Hsp27 leads to NfκB activation and subsequent expression of the
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proangiogenic factors VEGF and interleukin-8 (IL-8) in endothelial cells [22]. Together with
others, our group could show that an overexpression of Hsp27 is strongly linked to several be-
nign and malign pathologies of the lung associated with fibroblast activation, including emphy-
sema/chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis and non-
small cell lung cancer [21, 23–26].
Given the fact that activated fibroblasts play an important role in the progression of malig-
nant disease as well as in various non-malignant diseases of the lung, we aimed to investigate
the prevalence of Hsp27 positive tumor stroma in CRC lung metastases and corresponding pri-
mary tumors. Furthermore, we sought to describe the implications on the clinical outcome
after metastasectomy and the presence of cellular and secreted Hsp27 in these patients.
Materials and Methods
Study population
From April 2009 to November 2013, all consecutive cases of pulmonary metastasectomy from
primary CRC and appropriate tissue samples were included in this study. Patients received di-
agnostic work-up including thoracic and abdominal computed tomography (CT). If patients
had undergone pulmonary metastasectomy before, specimen of the first metastasectomy was
also examined and the date of the first metastasectomy was used for outcome calculation. Lung
metastasis free survival (LMFS) was defined as the time between diagnosis of the primary
tumor and diagnosis of the metastatic spreading to the lung. R0 resection was achieved in all
patients. Of 33 patients, specimens of the corresponding primary tumor could be obtained. Fol-
low-up examinations were carried out in 3 to 6 months intervals. Recurrence-free survival
(RFS) was defined as the period from the first pulmonary metastasectomy to evidence of recur-
rent disease at any site verified by CT scans. In 10 consecutive cases, serum samples obtained
before metastasectomy and during follow-up were available. Follow-up serum samples were
collected 3 to 6 months after surgery. Additionally, serum samples from age-, gender- and
smoking status- matched healthy volunteers were collected. All patients gave their written in-
formed consent prior to blood collection and participation. A study cohort of 25 consecutive
patients with resected CRC liver metastases served as additional control group. The study was
approved by the ethics committee of the Medical University of Vienna (EK 91/2006, EK1194/
2011 and EK1044/2012) and was conducted according to the declaration of Helsinki. The cur-
rent study cohort is based on previous published works by our group.[27, 28]
Immunohistochemistry and immunofluorescence
Immunohistochemical staining was performed according to a standard protocol. Shortly, for-
malin-fixed, paraffin-embedded tissue specimens were cut in 4-μm thick sections and deparaf-
finized. Heat-mediated antigen retrieval was performed. Endogenous peroxidase activity was
quenched with 0.3% hydrogen peroxide. Sections were incubated with the appropriate primary
antibody for 1h at room temperature. For immunohistochemistry, as secondary step, the poly-
mer- based ImmPRESS kit (Vector Laboratories, Burlingame, California) was used according
to the manufacturer’s protocol. 3,3’-Diaminobenzidine (DAB) was used as substrate (Vector
Laboratories, Burlingame, California). Finally, the sections were counterstained with hematox-
ylin. Vimentin staining was performed in a Ventana ES Immunostainer System (Ventana Med-
ical Systems Inc., Tucson, AZ, USA). For immunofluorescence, appropriate fluorescent
secondary antibodies were used and cell nuclei were counterstained with DAPI (Sigma Aldrich,
St. Louis, MO, USA). As negative controls, the primary antibody was omitted. Positive controls
were tissue samples with known presence of the respective target protein. A detailed list of anti-
bodies and dilutions is provided as supplementary information (S1 Table).
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Scoring of stained tumor cells. Immunohistochemistry staining score (IHC score) was
calculated as described previously [29]. The percentage of positive tumor cells could reach val-
ues between 0 and 100%, and were multiplied by the staining intensity (0 to 3). Thus, IHC
scores could range from 0 to 300. Two blinded observers rated the staining. In case that the two
ratings differed, the slide was discussed and re-evaluated. The continuous IHC score was di-
chotomized by applying the median score of metastases or primary tumors as cut-off value.
Scoring of stained stromal cells. The sections were scored semiquantitatively as described
previously [10]. Briefly, the slides were screened at low magnification and evaluated for their
staining intensity in the stromal cells in the tumor center. The stromal staining was assessed as
grade 0 (negative,<1% positive stromal cells), grade 1+ (low,1–10% positive stromal cells),
grade 2+ (intermediate,>10–50% positive stromal cells) and grade 3+ (strong,>50% positive
stromal cells) by two blinded observers. In case that the two ratings differed, the slide was dis-
cussed, re-evaluated and a consensus was reached on all slides.
Determination of microvessel density. Microvessel density (MVD) was measured using
the “hotspot”method, as published elsewhere [30]. In brief, the slides were screened at low
magnification to identify the area with the greatest number of CD31-positive microvessels
(“hotspot”). MVD was determined by counting all microvessels at 200x magnification (corre-
sponding to 0.95 mm2). Mean values were calculated from two independently counted densi-
ties. In case of strong inter-observer discrepancy, the slide was reevaluated.
Enzyme-linked immunosorbent assay (ELISA)
Serum samples were assessed by commercially available human Hsp27, phospho-Hsp27 and
interleukin-8 ELISA kits (all R&D Systems, Minneapolis, USA). Measurement was conducted
according to the manufacturer’s instructions. The samples were assayed in duplicates. The ab-
sorbance was measured at 450nm using a plate reader (PerkinElmer, Waltham, USA), com-
pared to a standard curve with known protein content and converted to pg/mL.
Statistical analysis
All obtained data was evaluated statistically using SPSS 19 (SPSS Inc., Chicago, USA) and
GraphPad Prism 6 (GraphPad Software Inc., California, USA). Student’s t-test was used to
compare means of two independent groups, paired t-test for dependent groups and expressed
as mean±standard deviation (SD). Kaplan-Meier curves and log-rank test were used to com-
pare survival functions. Chi-square test and Fisher’s exact test were used to compare binominal
variables. All tests were two-sided. P-values equal or below 0.05 were considered as
statistically significant.
Results
Tissue specimens of PM from a total of 51 consecutive patients were available. Median age at
metastasectomy was 63 years (range 33–83). 29 (56.9.1%) male and 22 (43.1%) female patients
were included. The clinicopathological characteristics of the included patients are summarized
in Table 1.
Hsp27 is highly expressed in cancer-associated stroma of lung
metastases
To assess the expression level of Hsp27 in cancer-associated stroma, tissue sections were
stained for Hsp27 and vimentin (Fig. 1). The Hsp27 expression of tumor stroma in PM was
scored in 0 (0%), 17 (33%), 17 (33%), 17 (33%) cases as 0, 1+, 2+ and 3+, respectively. The
Hsp27 in CRC Lung Metastases
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correlation of the stromal Hsp27 staining with patient and tumor characteristics is depicted in
Table 1. Staining intensity of the tumor cells was determined separately (S1A Fig). 23 (45%)
metastases were scored as Hsp27 highly positive and 28 (55%) metastases as low/negative (IHC
score range 0–160; median/cut off 30). There was no correlation between tumor and stromal
Hsp27 expression in pulmonary metastases (Chi square test; P = 0.237). 33 corresponding pri-
mary tumors were available. The stromal Hsp27 expression in the primary tumors 0 (0%), 6
(18%), 15 (46%) and 12 (36%) were scored as 0, 1+, 2+ and 3+, respectively. Determining the
Hsp27 staining in the tumor cells in the primary tumor tissue, 14 (42%) of the cases were
scored as Hsp27 positive and 19 (58%) as low/negative (IHC score range 5–100; median/cut off
70).
Hsp27 is co-expressed with α-SMA and vimentin in the stroma of PMs
Activated tumor stroma has been described as highly α-SMA positive in primary and metastat-
ic CRC [12, 31]. Therefore, the specimens were stained for α-SMA. The expression of α-SMA
in the stroma was rated in the same semiquantitative manner as the Hsp27 staining. 0 (0%), 13
(25.5%), 24 (51%) and 13 (25.5%) cases were scored as 0, 1+, 2+ and 3+, respectively. The stain-
ing score distribution according to the clinicopathological variables is depicted in Table 1.
Fig 1. Representative images showing pulmonary metastases with low, intermediate and high intensity of positive tumor stroma stained for
Hsp27 and α-SMA. Stromal fibroblasts were further identified by vimentin staining. (DAB substrate, same tumor specimen per row, 200x magnification).
doi:10.1371/journal.pone.0120724.g001
Hsp27 in CRC Lung Metastases
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Expression levels of α-SMA correlated significantly with Hsp27 expression in PMs (P< 0.001,
Fig. 2A). This was also observed in liver metastases (S2 Fig). To further assess the stromal co-
expression of α-SMA and Hsp27, representative slides of primary and metastatic tumors were
co-labeled for α-SMA and Hsp27 by immunofluorescence. A strong co-expression could be ob-
served especially in PMs (Fig. 2D). Tumor stroma with strong Hsp27 and α-SMA staining was
also highly positive for vimentin (S3 Table).
MVD is increased in tissue samples with Hsp27-positive tumor stroma
Recently it was shown that Hsp27 mediates angiogenesis [22]. We therefore determined the
MVD by CD31 staining and correlated it with the Hsp27 expressions (Fig. 2B and 2C). In PM,
we found a trend towards higher MVD in samples with high Hsp27 levels. MVD was 33.0±2.9,
40.1±3.8 and 43.0±4.7 for 1+, 2+ and 3+ Hsp27 intensity (mean±SD). However, this trend did
not reach the level of significance (P = 0.081). Similarly, in primary CRC with high stroma lev-
els of Hsp27, significantly more microvessels could be found (27.7±3.2, 37.2±4.0 and 46.4±5.2
for 1+, 2+ and 3+ Hsp27 intensity, respectively; P = 0.031). A detailed description of MVD
stratified by clinicopathological characteristics is provided in S2 Table.
Fig 2. The degree of Hsp27 expression score in the tumor stroma correlated significantly with the expression of stromal α-SMA (A). CD31-positive
microvessels surrounded by tumor stroma next to tumor cells (asterisk) (B). MVD was significantly increased in primary tumors and metastases with strong
stromal Hsp27 expression (C). Immunofluorescence showed a co-expression of stromal Hsp27 and α-SMA especially in PM (400x magnification) (D).
doi:10.1371/journal.pone.0120724.g002
Hsp27 in CRC Lung Metastases
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Stromal Hsp27 is associated with poor outcome after pulmonary
metastasectomy
We assessed the association of relevant clinicopathological variables with LMFS, RFS and OS
after metastasectomy (Table 2). No variable had significant impact on the LMFS. Female pa-
tients had a strong trend towards a shorter time to PMs (P = 0.091). The stromal expression of
neither α-SMA nor Hsp27 was associated with a significantly decreased LMFS. However, both
histological markers had a significant prognostic impact on the RFS after pulmonary metasta-
sectomy (P = 0.018 and P = 0.008 for stromal Hsp27 and α-SMA, respectively) (Fig. 3). Again,
female patients showed a strong trend towards decreased RFS. Moreover, patients with a histo-
ry of previous liver metastases had a decreased RFS compared to patients without liver metasta-
ses in the history. However, both variables, sex and the history of previous liver metastases, had
no significant influence on the RFS. Additionally to that, extensive stromal Hsp27 stromal
Hsp27 and α-SMA were associated with a decreased overall survival after metastasectomy
(P = 0.031 and P = 0.017 for stromal Hsp27 and α-SMA, respectively). Due to the high rate of
concordance, stromal Hsp27 and α-SMA were no independent factors in the outcome analysis
when adding both variables into a multivariate analysis (data not shown).
Table 2. Univariate analysis assessing clinicopathological variables and lungmetastasis free survival, recurrence free survival after metastasect-
omy and overall survival of patients (N = 51) with CRCmetastasizing to the lung.
Lung metastasis free survival Recurrence free survival Overall survival
Total Univariate analysis (log-rank) Univariate analysis (log-rank) Univariate analysis (log-rank)
N = 51 % Months HR (95% CI) p-value Months HR (95% CI) p-value Months HR (95% CI) p-value
Sex Male 29 43.1 24 1 0.091 17 1 0.125 39 1 0.464
Female 22 56.9 29 0.62 (0.35–1.09) 11 1.63 (ß.86–3.09) 52 0.72 (0.29–1.77)
Age (years) < 64 yrs 26 51.0 24 1 0.759 15 1 0.820 39 1 0.377
 64 yrs 25 49.0 28 0.92 (0.52–1.61) 11 0.93 (0.49–1.77) 65 0.67 (0.28–1.64)
Location Colon 27 52.9 28 1 0.926 15 1 0.730 52 1 0.671
Rectum 24 47.1 23 1.03 (0.58–1.81) 11 0.90 (0.47–1.70) 36 1.21 (0.50–2.93)
T stage pT1+pT2 8 16.7 24 1 0.932 15 1 0.977 31 1 0.650
pT3+pT4 40 83.3 25 1.03 (0.48–2.24) 14 0.99 (0.41–2.37) 52 0.78 (0.26–2.35)
unknown 3 -
N stage pN0 21 43.7 29 1 0.643 17 1 0.465 39 1 0.827
pN1+pN2 27 56.3 24 1.15 (0.64–2.07) 11 1.28 (0.65–2.50) 52 0.91 (0.37–2.23)
unknown 3 -
Previous liver metastasis Yes 16 31.4 25 1 0.691 9 1 0.118 30 1 0.401
No 35 68.6 24 0.89 (0.48–1.62) 17 0.60 (0.31–1.16) 52 0.69 (0.28–1.69)
stromal Hsp27 low 17 33.3 25 1 19 1 0.018a 52 1 0.031a
intermediate 17 33.3 28 0.80 (0.40–1.59) 0.575a 17 1.50 (0.68–3.48) NR 0.48 (0.13–1.70)
high 17 33.3 24 1.15 (0.58–2.26) 10 2.65 (1.31–6.77) 31 1.98 (0.75–5.37)
stromal alpha-SMA low 14 27.5 29 1 22 1 0.008a 52 1
intermediate 23 45.0 24 1.18 (0.60–2.30) 0.784a 15 1.83 (0.77–4.30) NR 0.58 (0.17–1.90) 0.017a
high 14 27.5 24 1.29 (0.61–2.72) 7 3.99 (1.53–10.41) 30 2.57 (0.84–7.84)
No. of nodules 1 33 64.7 25 1 0.278 15 1 0.490 52 1 0.653
>1 18 35.3 24 1.38 (0.76–2.50 = 14 1.26 (0.65–2.43) 36 1.23 (0.50–3.03)
LMFS <36 36 70.6 - - - 15 1 0.948 39 1 0.512
>36 15 29.4 - 11 1.02 (0.51–2.07) NR 0.72 (0.26–1.98)
doi:10.1371/journal.pone.0120724.t002
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Soluble Hsp27 is systemically increased in patients before pulmonary
metastasectomy
Elevated levels of soluble Hsp27 can be detected systemically in various malignant and non-
malignant diseases. In a subset of 10 of our patients paired serum samples (pre- and post-
metastasectomy) were available (Fig. 4). We compared the serum level of total Hsp27 and
phospho-Hsp27 to matched healthy volunteers (S3 Table). Serum total Hsp27 levels were 2276
±905, 3245±1684 and 2064±1226 pg/mL (mean±SD) for control, pre- and post-metastasect-
omy samples, respectively. Total Hsp27 decreased significantly after metastasectomy
(P = 0.016). Serum phospho-Hsp27 levels were 84±63, 156±82 and 88±114 pg/mL (mean±SD)
for control, pre- and post-metastasectomy samples, respectively. A significant difference was
found between healthy controls and pre-metastasectomy samples (P = 0.041). Although the
levels dropped after metastasectomy, the difference was not significant. IL-8, a proangiogenic
cytokine involved in the Hsp27 signaling, was detected at very low concentrations of 15±8, 45
±58 and 9±8 pg/mL (mean±SD) in the serum samples. The differences of systemic IL-8 levels
between the three groups did not differ significantly from each other. No correlation was found
between the expression level of stromal Hsp27, tumor Hsp27 and systemic levels (data not
shown). Moreover, no significant correlation between total or phospho-Hsp27 and standard
inflammatory markers (CRP and fibrinogen) was found (S1B and S1C Fig).
Fig 3. Kaplan-Meier plots showing the lung-metastasis free survival, recurrence free survival and overall survival after metastasectomy
dependent on stromal Hsp27 (A), stromal α-SMA (B) and tumor Hsp27 (C) scoring.
doi:10.1371/journal.pone.0120724.g003
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Stromal Hsp27 expression in pulmonary metastases is significantly
increased compared to liver metastases
We further evaluated the stromal expression of stromal Hsp27 and α-SMA in liver metastases
of 25 patients. Regarding the stromal Hsp27 expression 0 (0%), 12 (48.0%), 11 (44.0%) and 2
(8.0%) cases were scored as 0, 1+, 2+ and 3+, respectively. Stromal α-SMA expression was
rated as expression 0 (0%), 8 (32.0%), 11 (44%) and 6 (24.0%) cases were scored as 0, 1+, 2
+ and 3+, respectively. We found a strong correlation between stromal Hsp27 and α-SMA
(P< 0.001). Furthermore, stromal Hsp27 positivity was significantly more often found in pul-
monary metastases compared to liver metastases (P = 0.014), whereas this difference was not
significant for α-SMA (P = 0.625). Moreover, expression of Hsp27 in tumor cells (median 120
(range 0–270)) was significantly increased in liver metastases compared to pulmonary metasta-
ses (P = 0.037). We further analyzed the overall survival of the patients with liver metastases
depending on their stromal Hsp27, α-SMA and tumor Hsp27 expression, but significant differ-
ences were not found (S3 Fig).
Discussion
Distant metastases are the main cause of cancer-related mortality. Today, the tumor microen-
vironment and especially fibroblasts become of growing interest, providing additional informa-
tion on tumor behavior and potential therapeutic targets [32]. Myofibroblasts can be found in
Fig 4. Total Hsp27 (A), phospho-Hsp27 (B) and IL-8 (C) were measured in serum samples of healthy volunteers, patients with CRC lung
metastases before and 3months after metastasectomy (each n = 10; whiskers indicate standard deviation).
doi:10.1371/journal.pone.0120724.g004
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the microenvironment of various tumors and extensive fibroblast-activation could be linked to
rapid disease progression in malignant disease [32].
Herein we could demonstrate in a well-defined study cohort that vimentin+αSMA+ stromal
cells are highly present in pulmonary metastases of primary CRC. Wikberg et al. outlined that
myofibroblasts in the tumor center are a better prognosticator for poor prognosis than fibro-
blasts at the tumor margin [33]. We, therefore, restricted the scoring of the putative fibroblast
activation to the central portion of the tumor. Compared to Henry et al., who identified myofi-
broblasts by FAP-staining in primary colon cancer, we found a similar distribution of the stro-
mal scoring (0%, 20%, 38% and 35% for negative, low, intermediate and strong staining,
respectively). Additionally, they described the association of high amounts of activated fibro-
blasts with a decreased overall survival in patients with colon cancer, especially in the metasta-
sized situation [10]. This goes in line with our findings showing a decreased RFS after
pulmonary metastasectomy.
Interestingly, α-SMA positive phenotype of tumor-associated stroma was accompanied by
the expression of Hsp27. On the one hand, this small heat-shock protein has been examined in
CRC tumor cells themselves [34–36]. An increased expression of Hsp27 in tumor cells of pri-
mary CRC was described as negative prognosticator for survival [37, 38]. On the other hand,
Hsp27 expressing fibroblasts were examined in the context of wound healing and fibrosis. To
the best of our knowledge, stromal Hsp27 has not been described as a potential prognostic
marker in CRC. Interestingly, strong stromal Hsp27 expression was associated with high MVD
in the primary tumors (P = 0.031) and in PM (P = 0.081). Due to the strong correlation of
Hsp27 with α-SMA as an established marker for fibroblast activation, the over-expression of
Hsp27 was associated with significantly worse clinical outcome after pulmonary metastasect-
omy (median RFS 19, 17 and 8 months for 1+, 2+ and 3+, respectively), comparable to the
prognostic impact of stromal α-SMA expression. The decrease RFS was also translated in a sig-
nificantly different OS between the low, intermediate and high stromal Hsp27 or α-SMA, re-
spectively (Fig. 3). Similarly, Tsujino et al. described α-SMA positive fibroblasts as being
capable to predict disease recurrence in a cohort of patients with stage II and III primary CRC
[12]. Kahlert et al. demonstrated by microdissection of primary CRC, lung and liver metastases
that a panel of pro-angiogenic factors are differentially expressed in tumor cells and the stromal
compartment. The stromal expression of angiopoietin-2 in pulmonary metastases was an inde-
pendent prognosticator for poor survival after surgery in multivariate analysis (P = 0.044),
even in a rather small study cohort (n = 25) [39]. These findings support the results of our
work, in which we could describe Hsp27 as a further proangiogenic, stromal marker with prog-
nostic impact after metastasectomy. It is also important to mention, that Sato et al. described
high stromal expression of the description factors ETS1 as a predictor of CRC lung metastases
[40]. Interestingly, ETS1 is strongly interacting with the small heat-shock protein network
[41].
The analysis of blood samples in a subgroup of patients revealed that metastatic CRC is a
relevant inducer even of systemic Hsp27 expressions. The level of soluble total Hsp27 and
phospho-Hsp27, a polymerized form of Hsp27, significantly decreased after complete removal
of the PMs. Moreover, compared to a matched control group of healthy volunteers, pre-
operative total Hsp27 and phospho-Hsp27 levels were increased and dropped after surgery to
comparable low levels. Similar to our findings, Zhao et al. could demonstrate increased serum
levels of Hsp27 in ovarian cancer with peritoneal metastases. In the same work it was also
shown that the levels dropped after chemotherapy [42]. IL-8, which is thought to mediate local-
ly the proangiogenic effect of Hsp27, was also elevated before metastasectomy without reaching
significance [22]. Nontheless, the circulating levels of Hsp27 did not correlate with the stromal
or tumor expression. Furthermore it did not correlate with the systemic levels of CRP or
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fibrinogen. Thus, the circulating Hsp27 might be influenced by other factors like secretion,
degradation and elimination. Based on these preliminary results, further studies with adequate
cohort sizes will be necessary to further clarify the possible prognostic and predictive role of
circulating Hsp27 levels in patients with CRC.
In patients with CRC liver metastases the tumor stroma Hsp27+ vimentin+αSMA+ fibro-
blasts were less evident than in pulmonary metastases. In contrast to this, the Hsp27 expression
in tumor cells was significantly higher in resected liver metastases compared to pulmonary me-
tastases. This goes in line with the observation that the p38 MAPK signaling, a pivotal kinase
for Hsp27 phosphorylation and activation, is downregulated in CRC pulmonary metastases
compared to liver metastases [43].
The findings of this work are of translational relevance because of two aspects: first, Hsp27,
systemically, or confined to the tumor stroma, might possess potential prognostic and predic-
tive value. Pulmonary metastasectomy is a widely offered treatment option in patients with
CRC PM. However, the identification of patients who will benefit from surgery alone or an op-
tional adjuvant chemotherapy is a matter of current research [44]. Biomarkers like Hsp27
might help to identify patients with high risk of early recurrence of disease after surgery. Adju-
vant chemotherapy and a stringent follow-up could be offered to these patients. During the fol-
low-up of patients with malignant disease, serum markers, e.g. CEA, CA19–9 and beta-HCG,
are routinely used nowadays and additional markers might potentiate the accuracy of these es-
tablished markers. A limitation to this study is, that CEA and CA19–9 levels were not routinely
determined before metastasectomy. Correlation of these established tumor markers with
serum Hsp27 will be addressed in a future study.
Secondly, Hsp27 is a promising drug target. Apatorsen (OGX-427, Oncogenex, Bothell,
Washington, USA), a modified antisense oligonucleotide, binds to the Hsp27 mRNA tran-
script and therefore inhibits the Hsp27 expression [45]. Currently ongoing Phase II
studies are recruiting patients with advanced prostate, bladder, pancreatic and non-small cell
lung cancer [46]. The elevated expression levels of Hsp27 in the tumor-associated stroma
provide a rationale for the use of Hsp27 also in patients with primary CRC. Given that not
only CRC lung metastases, but also liver and lymph node metastases exhibit strong myofibro-
blast recruitment, especially patients with metastatic disease might benefit from Hsp27
inhibition.
In conclusion, we could demonstrate that Hsp27 is co-expressed with αSMA in the tumor
stroma of CRC lung metastases and, moreover, that its over-expression is associated with
worse clinical outcome after metastasectomy. Of note, soluble Hsp27 was also systemically
measurable, making serum Hsp27 a potential future serum marker in CRC.
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fibrinogen (n = 10) (B and C). Neither total Hsp27 (B), nor phospho-Hsp27 (C) correlated sig-
nificantly with CRP or fibrinogen.
(TIF)
S2 Fig. In CRC liver metastases stromal Hsp27 and α-SMA scoring correlated significantly
(n = 25) (A).
(TIF)
S3 Fig. The distribution of stromal Hsp27 (A) differed significantly in liver metastases
(n = 25) compared to lung metasatses (n = 51). This difference did not reach significance for
stromal α-SMA (B). Hsp27 expression in tumor cells was significantly higher in liver metasta-
ses compared to lung metastases (C). No significant differences were observed between the
subgroups regarding overall survival (D-F).
(TIF)
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